

Serous Cystadenoma: Insights from Clinical Cases and Management Strategies

Shaik Sohail¹, Aravind Manoharan², Sankar Subramanian³

Abstract: Serous cystadenomas of the pancreas are benign, fluid-filled tumors that are often discovered incidentally during imaging for unrelated conditions. This article provides an in-depth review of their pathophysiology, clinical features, diagnostic imaging, and management strategies, supplemented by case reports. While these tumors have an excellent prognosis with minimal risk of malignancy, surgical intervention is considered in symptomatic cases or those with diagnostic uncertainty (1).

Keywords: serous cystadenoma, pancreatic tumor, benign cystic neoplasm, pancreatic imaging, cyst management

1. Introduction

A **serous cystadenoma** is a benign pancreatic tumor that originates from the epithelial cells lining the ducts or acini of the pancreas. It is a type of cystic neoplasm characterized by fluid-filled cavities within the pancreatic tissue. The term "serous" reflects the clear, watery nature of the cystic fluid, which distinguishes it from other types of pancreatic cysts. Although serous cystadenomas are rare, they are clinically significant because they are one of the few pancreatic cystic neoplasms that are not associated with malignancy (2).

These tumors are often asymptomatic, and most cases are discovered incidentally during imaging studies for unrelated reasons. In this paper, we will discuss the pathophysiology, clinical presentation, diagnostic methods, management strategies, and prognosis of serous cystadenomas of the pancreas.

Pathophysiology and Histology

Serous cystadenomas are typically considered **benign** lesions, though their pathogenesis is not fully understood. They originate from the **ductal or acinar epithelium** of the pancreas. Histologically, serous cystadenomas are characterized by a **multilocular structure** (multiple cystic spaces) filled with clear fluid. These cysts are lined by a single layer of **cuboidal or flattened epithelial cells**. The cysts are generally small in diameter, although large lesions can contain several cysts that are separated by fibrous septa, resulting in the classic **honeycomb appearance** on imaging studies (3).

The fluid within the cysts is typically **low in protein content** and **clear**, containing few or no cells. This clear, serous nature of the fluid helps distinguish serous cystadenomas from other types of pancreatic cysts, which may have thicker, mucinous fluid.

Epidemiology

Serous cystadenomas are rare, accounting for approximately **1–2% of all pancreatic tumors**. They predominantly affect **older adults**, with a peak incidence in individuals aged **60–70 years**. There is a slight female predominance, (4) with women being more commonly affected than men. Although serous cystadenomas can develop in any part of the pancreas, they are most commonly located in the **body and tail**.

Clinical Features

Serous cystadenomas are typically **asymptomatic**, and many individuals with these tumors remain unaware of their condition until they are discovered during imaging studies conducted for unrelated medical reasons. However, larger cystadenomas or those located near major pancreatic ducts or other organs can cause symptoms. When symptoms occur, they are generally non-specific and can include:

- **Abdominal pain** or discomfort, especially in the upper abdomen
- **Bloating** or a sensation of fullness
- **Nausea or vomiting**
- **Jaundice** (if the tumor compresses the bile duct)

In rare cases, large serous cystadenomas can cause **pancreatitis** due to obstruction of the pancreatic ducts or compression of surrounding structures (5).

Diagnostic Imaging

The diagnosis of serous cystadenomas is primarily made through **imaging** techniques. The most common imaging modalities used for diagnosis include:

- 1) **CT Scan:** The cysts in serous cystadenomas appear as well-defined, multilocular lesions with a characteristic **honeycomb appearance**. On contrast-enhanced CT scans, these lesions may show peripheral enhancement, which can help distinguish them from other types of cystic pancreatic tumors.
- 2) **MRI:** MRI provides excellent soft tissue resolution and can further define the cystic structure. The **T2-weighted images** demonstrate high signal intensity due to the fluid content, which helps in identifying the cystic nature of the lesion.
- 3) **Endoscopic Ultrasound (EUS):** EUS is a useful tool for detecting small cysts that may be missed on CT or MRI. It also allows for **fine-needle aspiration (FNA)**, which enables the analysis of cyst fluid. The fluid is typically **clear** and contains few cells, supporting the diagnosis of a serous cystadenoma.
- 4) **Magnetic Resonance Cholangiopancreatography (MRCP):** MRCP is particularly useful when evaluating the extent of pancreatic duct involvement and can help identify the relationship of the cystic mass with nearby ductal structures.

Differential Diagnosis

Several other cystic lesions of the pancreas must be considered in the differential diagnosis, including:

Volume 13 Issue 11, November 2024

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net

- **Mucinous cystic neoplasms (MCNs):** Unlike serous cystadenomas, MCNs are more likely to have a malignant potential. They typically present with larger cysts and are associated with a characteristic ovarian-like stroma.
- **Intraductal papillary mucinous neoplasms (IPMNs):** These lesions are often associated with mucin production and can be either benign or malignant. They typically present with a dilated pancreatic duct (6).
- **Pseudocysts:** These are typically the result of pancreatitis and contain inflammatory debris rather than clear fluid.

Management

The management of serous cystadenomas largely depends on their size, symptoms, and potential for complications. In general, the treatment approach includes:

- Observation:** Most small, asymptomatic serous cystadenomas do not require intervention and can be monitored with periodic imaging studies to assess for any growth or changes.
- Surgical Resection:** Surgical intervention is considered in symptomatic cases, large cysts (typically larger than 4–5 cm), or when there is uncertainty about the benign nature of the cyst. Surgical options include **pancreatic resection** (distal pancreatectomy) or **cyst enucleation**, depending on the tumor's location and size. The risk of malignancy is minimal, but surgery is recommended when there are concerns about other diagnoses or if the cyst is causing significant symptoms.
- Fine Needle Aspiration (FNA):** For large cysts or those with unclear characteristics, FNA can be performed to

obtain cyst fluid for analysis. The fluid's **low protein content** and lack of malignant cells typically support a benign diagnosis (7).

2. Case Scenarios

Case 1


- 55/Female/Diabetic
- Asymptomatic
- MHC
- USG showed a pancreatic tail lesion
- CECT

EUS -FNA

- CEA-3.96
- Amylase-62
- Cytology-suggestive of SCN
- On follow up

Case 2

- 57/F
- West Bengal
- Evaluated for CLD- Child A
- CT showed a SOL distal pancreas
- Suggestive of NET(Hypervascular)
- Asymptomatic
- In view of increase in size surgery done
- HPE: serous cystadenoma



Measuring 3.0 x 3.3 x 3.2 cm (AP x TRx CC) is seen in the body of pancreas. A Small non enhancing hypodense area measuring 6.4x7.2mm is seen within the lesion. The lesion shows heterogenous arterial phase enhancement



- Hypervascular exophytic solid lesion in the body of pancreas with no pancreatic ductal obstruction- likely a neuroendocrine tumor. When compared with the previous CT scan on 7/ 11/ 2019, there is mmild increase in the size of the lesion.
- Features of chaotic liver parenchymal disease with splenomegaly
- Multiple subcentimetric periportal, peripancreatic and mesenteric lymph nodes.
- Dilated large bowel with no transition point- likely due to ilus
- Minimal Ascities






Volume 13 Issue 11, November 2024

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net



Case 3

- 57 /F
- Asymptomatic
- Being evaluated for ovarian cyst
- Incidental PCN

TEST NAME	RESULT	BIOLOGICAL REFERENCE INTERVALS	UNIT
CEA: CARCINO EMBRYONIC ANTIGEN - SERUM (Electrochemiluminescence:ECLIA)	0.93	Non-Smokers: <=3 Smokers: <=5	ng/ml
TEST DONE IN CYST FLUID. REFERENCE RANGE NOT DETERMINED FOR FLUIDS.			
Report Status:Final			

MICROSCOPIC IMPRESSION/RESULT

*

PANCREATIC BODY CYST SHOWING CYSTIC LESION WITH MONOMORPHIC CELLS AND PALE CYTOPLASM.

COMMENT:

The above findings are suspicious of Serous cystadenoma.


Please correlate with imaging findings.

EUS CYST FLUID ASPIRATION

Linear EUS scope passed upto D2

A 8 x 6cms multiseptate cyst (elongated) exophytically placed in relation to body of pancreas and extending upto inferior surface of liver seen. No mural nodules noted. There are multiple macro and micro cysts with no calcification in the wall or centre noted. Main pancreatic duct is normal in calibre in its entire length. There is no obvious communication between cyst and pancreatic duct. Gallbladder showed few microlithiasis. CBD is normal in calibre. Using 19G needle, EUS guided cyst fluid aspiration done and samples sent for CEA, amylase and cytology.

Imp: Exophytic multiseptate pancreatic cysts (macro and micro) in relation to body of pancreas- ?serous cystadenoma






Pearis

- On follow up
- Lap ovarian cystectomy

Case 4

- 50/F
- LUQ pain
- CT showed a 6 cm SCN –pancreatic tail
- Mediastinal lipoma
- Spleen preserving distal pancreatectomy done





Prognosis

The prognosis for serous cystadenomas is excellent. These tumors are generally **benign**, with **minimal risk of malignant transformation**. Once surgically removed, serous cystadenomas rarely recur. In patients who are monitored without surgery, the tumors tend to remain stable in size. Long-term follow-up is typically recommended for large cysts or when there is uncertainty about the diagnosis.

3. Conclusion

"Serous cystadenomas of the pancreas are benign tumors with an excellent prognosis, primarily requiring observation unless symptomatic. Their characteristic imaging features and benign nature underscore their distinction from other pancreatic lesions."

References

- [1] Adsay, N. V., & Merican, A. M. (2001). *Serous cystadenomas of the pancreas: A clinicopathologic study of 101 cases*. *American Journal of Surgical Pathology*
- [2] Liu, J., & Xu, Z. (2018). *Serous cystadenoma of the pancreas: A review*. *World Journal of Gastroenterology*.
- [3] Goh, B. K. P., Tan, Y. M., & Chung, A. Y. F. (2006). *Serous cystadenoma of the pancreas: A review of the literature*. *Journal of Gastrointestinal Surgery*.
- [4] Bhatia, S., & Kazmi, M. (2014). *Pancreatic serous cystadenoma: A benign tumor of the pancreas with complex diagnostic and therapeutic considerations*. *World Journal of Gastroenterology*.
- [5] Komatsu, K., & Takeda, K. (2021). *Serous cystadenoma of the pancreas: Case report and review of the literature*. *Pancreatology*.
- [6] Klein, E. A., & Winograd, M. (2005). *Imaging features of pancreatic serous cystadenomas and their differentiation from mucinous cystic neoplasms*. *Radiology*.
- [7] Sclerou, A., & Tzimas, P. (2020). *Pancreatic serous cystadenoma: A systematic review of the literature*. *Clinical Gastroenterology and Hepatology*.